Incyte Corporation (BIT:1INCY)

Market Cap	16.51B +23.9%
Revenue (ttm)	4.38B +21.2%
Net Income	1.10B +3,845.0%
EPS	5.46 +4,173.3%
Shares Out	n/a
PE Ratio	15.06
Forward PE	12.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	183
Average Volume	20
Open	91.84
Previous Close	91.80
Day's Range	87.84 - 91.84
52-Week Range	47.33 - 96.00
Beta	n/a
RSI	44.47
Earnings Date	Feb 10, 2026

About Incyte

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhib...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1991
• Employees: 2,617
• Stock Exchange: Borsa Italiana
• Ticker Symbol: 1INCY

Financial Performance

In 2025, Incyte's revenue was $5.14 billion, an increase of 21.22% compared to the previous year's $4.24 billion. Earnings were $1.29 billion, an increase of 3844.96%.

Financial numbers in USD